Does A New Cellulose Dressing Have Potential In Chronic Wounds?
- Volume 17 - Issue 3 - March 2004
- 8090 reads
- 0 comments
The preclinical animal testing and biocompatibility testing have shown no evidence of delayed dermal contact sensitization in the guinea pigs, and there was no evidence of significant irritation or toxicity when it was injected subcutaneously into rabbits. The cytotoxicity of the dressing with mammalian cells showed no cytotoxicity and did not inhibit cell growth. The cellulose wound dressing successfully passed all of these tests, ensuring that the product is biocompatible, safe and will not inhibit wound healing.
During human clinical trials, the cellulose wound dressing exhibited strength in removing slough necrosis in deep pressure ulcers. It also reduced the hypergranulation tissue down to the level of the surrounding epithelium. Researchers found the dressing also helped promote autolytic debridement and provided a moist wound environment to maintain a healthy granulation tissue base. The wound dressing also aids in cleansing wound margins to help epidermal migration, which leads to wound size reduction and the healing of various chronic wounds.
Case Study: How XCell Can Aid Ulcer Healing
A 66-year-old Hispanic female presents to our office with a non-healing ulcer to the plantar aspect of the left hallux. She has been treated by a general surgeon since 1996 for this condition. The patient has undergone several debridements and hospitalizations with IV antibiotic therapy. She has also used orthotics to reduce pressure to this area. A biopsy of the ulceration showed squamous epithelial hyperplasia, parakeratosis and marked inflammation.
Her past medical history includes IDDM for 16 years, HTN, hyperlipidemia and depression. The patient underwent a left breast mastectomy and is currently undergoing chemotherapy. She also experienced renal failure and is undergoing renal dialysis with the fistula in the left upper arm. Her current medications include insulin and a HTN medication. The patient does not know the name of the HTN medication. She denies using tobacco and alcohol. The patient was scheduled for X-rays, lab work with CBC w/diff, A1c and noninvasive vascular studies. She reports a random blood sugar of 120 to 140.
The physical exam reveals a frail woman, who is cooperative and oriented. She is concerned that her toe will need to be amputated, which is adding to her stress and depression. The exam of the lower extremity shows nonpalpable pulses. Her skin temperature is warm proximal to distal with equal and adequate hair distribution to bilateral limbs and toes. There are no foot deformities other than the ulceration to the left plantar hallux and edema to the entire left hallux. There is no cellulitis. We did note mild erythema distal to the first metatarsophalangeal joint.
The wound itself is 3 cm in diameter with a thick callus rim and 2 mm deep. The base of the wound appears macerated with white and yellow fibrotic tissue with bleeding within the hyperkeratosis layer. The wound did not bleed with debridement. There was a foul odor during the debridement but no drainage.
Proceeding With Treatment
We emphasized an initial home care regimen, having the patient apply enzymatic debridement ointment daily with saline moistened gauze and Kling wrap. We ordered a wheelchair for the patient to faciliate offloading.
The X-ray findings do not show evidence of acute or chronic osteomyelitis. They did reveal diffuse osteopenia. Her labs were normal and, as expected, the noninvasive vascular study is abnormal with moderately severe occlusive disease, femoral-popliteal disease. The left ABI is 0.41 mmHg.